Loading...
Loading...
BVXV| Name | Value |
|---|---|
| Revenues | 2,016.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 2,016.0K |
| Operating Expense | 3,186.0K |
| Operating I/L | -3,186.0K |
| Other Income/Expense | -329.0K |
| Interest Income | 0.0K |
| Pretax | -3,515.0K |
| Income Tax Expense | 329.0K |
| Net Income/Loss | -3,844.0K |
BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company based in Israel, specializing in the development, manufacturing, and commercialization of products for the prevention and treatment of infectious diseases and other illnesses. The company's focus lies in the development and commercialization of COVID-19 nanosized antibody (NanoAb) through licensing and collaboration agreements with Max Planck Society and University Medical Center Göttingen. Additionally, BiondVax Pharmaceuticals is also engaged in the development and commercialization of NanoAbs for various other disease indications, positioning itself as a key player in the biopharmaceutical industry.
